Table 1.

Correlation of ERG splice variant expression and type I/type II ratio with clinicopathologic characteristics

Clinicopathologic characteristicsERG splice variant expression
Type I/ type II ratio
No (46)Yes (76)P*n (76)MedianP
Race0.03450.1142
    Caucasian29 (33%)59 (67%)590.51
    African American15 (56%)12 (44%)120.33
Family history0.63120.3259
    No28 (38%)45 (62%)450.52
    Yes10 (33%)20 (67%)200.51
Pathologic T stage0.53180.2541
    pT214 (36%)25 (64%)250.44
    pT329 (42%)40 (58%)400.51
Pathologic Gleason sum0.00230.0323
    2-69 (24%)29 (76%)290.35
    720 (36%)36 (64%)360.46
    8-1014 (70%)6 (30%)60.70
LCM differentiation0.00580.0067
    Well31 (32%)66 (68%)650.45
    Poorly15 (62%)9 (38%)90.76
Margin status0.94360.0032
    Negative28 (38%)45 (62%)450.39
    Positive16 (39%)25 (61%)250.57
PSA recurrence0.73120.0456
    No33 (37%)56 (63%)560.42
    Yes11 (41%)16 (59%)160.61
  • NOTE: ERG splice variant expression (N = 122): In comparison with patients with no detectable expression of ERG in their prostate cancer cells (n = 46), the ERG-positive patient cohort (n = 76) has a decreased proportion of patients with high Gleason grade, poor prostate cancer cell differentiation, and African American ethnicity. Type I/type II ratio (n = 76): The ratio of ERG type I/type II splice variants in prostate cancer cells is increased in patients with poor tumor cell differentiation and with prostate-specific antigen recurrence.

    Abbreviation: PSA, prostate-specific antigen.

  • * Two-sided test, P < 0.05 was considered statistically significant.

  • One-sided test, P < 0.05 was considered statistically significant.